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Background 
The wide spectrum of plasma cell dyscrasias includes the PCM, 
as the second most frequent haematological malignancy, and its pre-
malignant conditions the MGUS and SMM [1]. Uncontrolled clonal 
proliferation of plasma cells and infiltration to bone marrow cause such 
end-organ damages as anaemia, hypercalcaemia, renal failure and bone 
disease [1]. By definition, MGUS and SMM are asymptomatic diseases 
and they do not exhibit end-organ damages [1]. 
The bone disease is the most frequent appearance of the multiple 
myeloma which occurs approximately in two-thirds of patients at the 
time of diagnosis and occurs almost in all patients during the course 
of the disease [2,3]. The bone involvement in myeloma substantially 
impairs the life quality and it is considered to the major cause of 
morbidity and mortality. Presence of lytic bone lesion calls for an 
immediate start of systemic therapy. The skeletal X-ray survey has been 
used for screening for a long period of time because it is widely available, 
simple, operates at low cost and characterized by low radiation dose. 
Lytic lesions only becoming evident at skeletal X-ray when more than 
30-50% of the bone mineral density has already been lost [3], thus the 
skeletal survey underestimates the presence of lytic bone disease in a 
significant proportion of the patients. In a systematic review, Regelink 
et al. [4] have drawn a comparison between such modern imaging 
techniques as the MRI, the whole body low dose CT (WBLDCT), the 
PET/CT and the conventionally used radiography. The newer imaging 
methods had higher sensitivity than the skeletal survey, resulting as 
many as 80% or more efficiency in lesion detection [4]. The skeletal 
radiograms, the PET/CT and WBLDCT images were accepted as 
diagnostic evidence for the end-organ damages in PCM and they got 
proposed to use in the recommendation of the International Myeloma 
Working Group (IMWG) in 2014 [1]. The combination of PET with 
MRI has provided information simultaneously. The PET/MRI has had 
higher potential in the assessment of bone and bone marrow lesions 
and it secured a higher lesion detectability and diagnostic confidence 
in comparison to the performance of the PET/CT [5].
In our prospective study, the first cluster of our aims was the 
efficacy evaluation of the 18F-FDG PET/CT and PET/MRI in detection 
of early lesions of bones and skeletal structures of patients with MGUS 
and SMM. Our second bunch of goals was to assess and compare 
the PET/CT and PET/MRI data in symptomatic-myeloma-multiple 
bone lesions, based on qualitative (lesion detection) and quantitative 
(lesional SUVmax, metabolic tumor volume) manners. 
*Corresponding author: Péter Rajnics, Department of Haematology, Móritz 
Kaposi Hospital, H-7400 Kaposvár Tallián Gyula str. 20-32, Hungary, Tel: 0036-
82/501-341; Fax: 003682501-344; E-mail: rajnicsp@hotmail.com
Received March 10, 2018; Accepted March 21, 2018; Published March 28, 2018
Citation: Rajnics P, Tóth Z, Zádori P, Repa I, Kovács A, et al. (2018) Can 18F-FDG 
PET/MR Imaging Contribute to the Assessment of Bone Lesions in Patients with 
Plasma Cell Dyscrasias?. J Blood Lymph 8: 209. doi:10.4172/2165-7831.1000209
Copyright: © 2018 Rajnics P, et al. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Can 18F-FDG PET/MR Imaging Contribute to the Assessment of Bone 
Lesions in Patients with Plasma Cell Dyscrasias?
Rajnics P1*, Tóth Z2,4, Zádori P3, Repa I2,3,4, Kovács A3,4, Moizs M1 and Egyed M1
1Móritz Kaposi General Hospital, Department of Haematology, Kaposvár, Hungary
2PET Medicopus Ltd. Kaposvár, Hungary
3Kaposvár University, Health Center, Institute of Diagnostic Imaging and Radiation Oncology, Kaposvár, Hungary
4Faculty of Health Sciences, Doctoral School, University of Pécs, Pécs, Hungary
Abstract
Objective: Two patient groups were studied for evaluation of detection efficacy of 18F-fluorodeoxyglucose 
positron emission tomography/magnetic resonance imaging (18F-FDG PET/MRI). The first group was dedicated to 
assess the possible early bone lesions of those patients who had been diagnosed with monoclonal gammopathy 
of undetermined significance/smouldering multiple myeloma (MGUS/SMM). In the second group, the detection 
sensitivity of the PET/CT and PET/MRI for bone lesions was compared to each other in patients with symptomatic 
plasmacytic myeloma (PCM).
Methods: 14 patients with MGUS/SMM and 27 patients with PCM were enrolled in this study. Initially, all patients 
underwent an 18F-FDG PET/CT examination and it was followed by a PET/MRI imaging.
Results: No bone lesion was detected with PET/CT and PET/MRI in patients either with MGUS and SMM. Bone 
marrow alteration was also not detected with PET/MRI in this group. Disease progression has not been revealed in 
the course of the 18 months follow-up period. 
In regard to lesion detection, there was no difference between the PET/CT and PET/MRI in the symptomatic 
PCM group. The metabolic tumor volume (MTV) was found to be strongly correlating with both the β2-microglobulin 
serum level and the ISS stage.
Conclusion: PET/MRI is a reliable diagnostic tool for detection of bone lesions in plasma cell discrasias, and it 
is not inferior to the PET/CT imaging. The MTV measurement can provide a promising diagnostic tool for the direct 
assessment of myeloma tumor loading in the future.
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Patients and Methods
Patients
Patients with monoclonal gammopathy were included in the study. 
Eligibility criteria included: the age of 18 years or above, previous 
laboratory and pathological confirmation of monoclonal gammopathy 
based on the recommendations of the International Myeloma Working 
Group [1]. All the study participants were newly diagnosed patient. 
The study was conducted according to the rules of good clinical and 
laboratory practice and the principles of the Helsinki Declaration. 
Written informed consent was obtained from the patients after that 
the purpose, nature and potential risks of the study had been explained 
to them and an institutional approval had also been issued by the local 
ethics committee. Diabetics, as well as patients representing general 
contraindications for MRI (e.g., pacemaker or internal metal fixateur) 
were excluded from the study.
Data acquisition
4.2.1 PET/CT: After intravenous injection of an average 280 MBq ± 
89 MBq 18F-fludeoxyglucose tracer, whole-body 18F-FDG PET/CT was 
performed on a Biograph Truepoint 64 scanner (Siemens, Healthcare 
GmbH, Erlangen, Germany) within 67 ± 15 minutes. The blood glucose 
level of patients was duly controlled by samplings and kept under 200 
mg/dL. The CT component of 18F-FDG PET/CT was acquired using 
the manufacturer-supplied dose reduction software CareDose 4D 
(Siemens Healthcare GmbH, Erlangen, Germany) with pre-sets of 
120 kV and 60 reference effective mAs. The PET data acquisition was 
performed in 10-15 bed positions (3 min per bed position for torso and 
1.5 min per bed position for lower extremities) in axial field of view 
(FOV): 16.2 cm, having matrix size 168 × 168 and a Gaussian filter 
of 4 mm Full Width at Half Maximum (FWHM). Iterative ordered 
subset expectation maximization algorithm (OSEM) reconstruction 
(3 iterations and 8 subsets) was applied. Attenuation correction was 
calculated based on the obtained CT datasets. 
PET/MRI: The whole-body 18F-FDG PET/MRI examinations were 
performed on an integrated 3 Tesla PET/ MRI scanner (Biograph mMR, 
Siemens Healthcare GmbH, Erlangen, Germany) without contrast 
agent administration, and obtained with an average delay of 70 ± 57 
minutes after the end of the PET/CT. No additional tracer was injected 
for the subsequent PET/MRI examinations. PET images were obtained 
in 3D mode, and got reconstructed using the OSEM algorithm, 3 
iterations and 21 subsets, having a Gaussian filter with 4mm FWHM 
and a 172 × 172 image matrix. The PET data acquisition was performed 
in 9-11 bed positions (5 min per bed position). For MR-based PET 
attenuation, correction a two-point (fat, water) coronal 3D-DIXON-
VIBE sequence was performed to generate a four-compartment model 
(background air, lungs, fat and muscle). The MRI data were obtained 
simultaneously including axial T1-weighted DIXON, coronal T2-
weighted turbo-inversion-recovery-magnitude (TIRM) and axial DWI 
sequences as well, and for the vertebral column addition sagittal TIRM 
sequence was obtained. Both PET systems (from PET/CT and PET/
MRI) were cross-calibrated by an activity-meter.
Data Analysis
Diagnostic images were evaluated using a dedicated Syngo.via 
software package (Siemens, Erlangen, Germany). Patient and lesion-
based analyses of PET/CT and PET/MR images were performed 
separately to avoid recognition bias. The first session had comprised 
interpretation of the PET/CT images, and after 2 months the PET/MRI 
images were evaluated. A nuclear medicine physician and a radiologist, 
with more than 10 years of experience, visually analysed the images of 
the patients in random order, searching for myeloma suspicious foci. 
Lesion characterization was based on both metabolic and morphologic 
criteria and consensus was reached between the readers. Lesions likely 
to have other benign aetiology were excluded. 
Measurement of MTV 
For Metabolic Tumor Volume assessment, a dedicated Syngo.
via MM Oncology application (version: VB 10, Siemens, Erlangen, 
Germany) was used. MTV was defined as it had been proposed by 
Fonti et al. [6]. Spheric volume of interest (VOI) was placed around 
each focal PCM lesions and VOI related SUVmax was calculated. All 
spatially connected voxels were added to the volume exceeding 40% of 
SUVmax level. Patient related overall MTV consisted of the sum of all 
measured lesion MTVs. 
Statistical Analysis 
For all the statistical analysis, R-software environment for 
statistical computing (version 3.3.0, R Foundation for Statistical 
Computing, Vienna, Austria) based on in-house developed programs 
were used. The statistical evaluation was performed using descriptive 
statistics, and Spearman’s rank correlation analysis. The cut-off value 
of significance was p<0.01.
Results
41 patients (24 male, 17 female; mean age 64.5 years) with 
monoclonal gammopathy were enrolled to the study. The main 
characteristics of the included patients are shown in Table 1. The PET/
CT and PET/MRI images were of good diagnostic quality having no 
artefacts in any cases. The cytogenetic results of the MGUS and SMM 
patients were normal. According to the ISS staging system, 8 patients 
have suffered from stage I, 10 patients from stage II and 9 patients from 
stage III PCM. The mean B2 microglobulin level was 3.8 mg/L in the 
multiple myeloma group (ranged: 2.9-7.2 mg/L). 
All patients got characterized by both PET/CT and PET/MRI 
imaging, being either positive or negative case. All 14 patients with 
MGUS/SMM had negative 18F-FDG bone marrow uptake pattern in 
both modalities. They had neither osseal nor extraosseal plasmocytoma. 
Their disease characteristics (M-component, lack of end-organ disease) 
had remain stable during a mean of 19 months after imaging. Two 
patients with SMM had no skeletal lesion on skeletal survey X-ray 
examination, however, they had a PET-negative skeletal lesion on CT-
scan and a positive marrow pattern on MRI. Despite the presence of 
Monoclonal gammopathy Mean age 
(years)
Sex (M/F) ISS stage Mean of B2 
uglobuline (mg/L)
CRAB-criterias positive (number of patients)
   I II III  Hyper-calcaemia Renal Anemia Bone
MGUS 66.5 7/5    2.1 no no no no
SMM 61.2 1/1 2   2.3 no no no no
Multiple myeloma 63.8 16/11 8 10 9 3.8 4 9 7 10
Table 1: The main characteristics of the patients with MGUS, SMM and MM.
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bone and marrow lesions, these PET-negative patients did not progress 
to symptomatic myeloma during the 1.5 years observation period. 
Before the start of anti-myeloma treatment, the 27 patients with 
multiple myeloma were examined by both modalities. The main disease 
characteristics are shown in Table 2.
The skeletal survey found lytic lesions in 10 patients (7 lytic lesions 
on the skull, 2 femoral, 1 lumbar spinal, 1 right rib and 2 pelvic lytic 
lesions). The PET/CT and PET MRI found more lytic lesions than 
the conventional skeletal survey (Figure 1). Figure 2 shows the PET-
positive lesions of a patient, who has had a negative skeletal survey. 
81 bone lesions related to myeloma were revealed by PET/CT in 
27 patients. All the 81 lesions, which were detectable with PET/CT, 
were also found and described with PET/MRI in a later assessment. 
Regarding the 18F-FDG bone marrow uptake pattern, 2 patients 
demonstrated a negative result, 17 patients a focal pattern, 4 patients 
a diffuse one and 4 patients a mixed pattern of tracer uptake in both 
modalities. 
The mean of SUVmax values of skeletal lesions was 6.55 (ranged 
from 3.4-17.9). The SUVmax values did not correlate significantly with 
any clinical parameters.
The whole-body MTV values ranged from 11.9 to 3778 cm3, with 
an average of 801.21 cm3. We have found a statistically significant 
correlation between the MTV and β2 microglobulin levels (r=0.86) 
(Figure 3) and between the MTV and ISS stage (r = 0.87) using 
Spearman analysis. 
Discussion
Importance of the 18F-FDG PET and the PET/CT examinations 
in evaluation of PCM bone lesions remarkably increased in the last 
few years. PET/CT has high sensitivity to detect both medullary and 
extramedullary myeloma. Its role in the treatment response assessment 
and prognostic value have been documented in several papers [3,4,7,8]. 
In a recent report, on 149 patients with smouldering myeloma, the 
presence of focal lesions on whole-body MRI was the strongest adverse 
prognostic factor for subsequent progression to symptomatic myeloma 
[9]. 
PET/MRI is a novel combined functional imaging method, which 
could evaluate the microcirculation within the bone marrow and the 
diffusion of interstitial water molecules and glucose uptake, as they are 
surrogate markers for tumour activity [10,11]. Sachpekidis et al. [10] 
assessed the feasibility of use, the image quality and reproducibility of 
the 18F-FDG PET/MRI method in 30 multiple myeloma patients.
MGUS is an asymptomatic plasma cell dyscrasia which has an 
average multiple myeloma progression risk of 1% per year [12]. 
Another asymptomatic plasma cell disorder is the SMM, which in 
comparison to MGUS is characterised with a higher risk of progression 
(10% per year) to PCM [13].
In these precursor diseases, due to the lack of end-organ damage 
such as lytic bone lesions, the “watch and wait” strategy is the 
cornerstone of the management. During this observation period, 
repeated laboratory investigations and skeletal surveys are needed. 
Paraprotein type IgA-kappa 6
IgA-lambda 2
IgG-kappa 9
IgG-lambda 4
Kappa 2
Lambda 3
Non-secreter 1
Mean serum calcium (mmol/L)  2.38
Mean serum creatinine (umol/L)  97.4
Mean hemoglobine concentration (g/L)  107.93
Mean bone marrow clonal plasma cell 
infiltration (%)
 68
Cytogenetics normal 18
hyperdiploid 7
t(11:14) cyclin D1 upreg. 1
t(14:16) MAF 1
t(4:14) FGFR3 upreg. 0
Table 2: The main disease characteristics of patients with MM.
Figure 1: Distribution of focal lesions by sceletal regions detected by sceletel 
survey, PET/CT and PET/MRI. The positivity means that minimum one lesion 
was detected in a given patient in demonstrated region. The total amount 
of lytic lesions of each regions are not showed on figure. The new imaging 
techniques demonstrate more lesions, than conventional sceletal survey in all 
examined regions. There was no difference between the lesion detection of 
PET/CT and PET/MRI.
Figure 2a: Coronal CT, PET and PET/CT images. Focal radiopharmacon activity increase without structural change in right femur.
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The latter is the gold standard imaging modality for detection of 
osteolytic lesions, however it is not sensitive enough for detection of 
early osteolytic lesions requiring at least 30% cortical bone destruction 
[14] for a positive finding. This technique can detect neither intra- nor 
extramedullary disease. Therefore, it is difficult to determine that exact 
time point when the active treatment should be introduced. The new 
imaging techniques detect early bone lesions in plasma cell dyscrasias 
and therefore clinical investigations have already been started to assess 
their role in the assessments of these clinical conditions. 
In our preliminary study the hybrid PET/MRI system provided 
good image quality in all cases without artefacts. None of the detection 
techniques, either the X-ray skeletal survey or the PET/CT and PET/
MRI, detected skeletal lesions in our patients with MGUS. According to 
the repeated 3 months interval laboratory follow-up, these patients did 
not show progress at an average of 19 months period after imaging. The 
two SMM patients had negative findings for a lesion on skeletal survey, 
however, they had skeletal lesions on the CT-scan and positive bone 
marrow pattern by MRI. However, these lesions were PET-negative. 
During 1.5 years observation period PCM did not developed in these 
patients. These results showed that the premalignant PET-negative 
plasma cell dyscrasias did not progress to symptomatic myeloma for a 
long period of time. Therefore, longer follow-up is needed to find the 
exact time-point when the progression may occur.
We demonstrated that the 100% of all focal lesions were found 
by PET, independently whether it had belonged to either PET/CT 
or PET/MRI imaging systems. Our results confirm the findings of a 
similar study by Sachpekidis et al. [10] in which the PET parts of PET/
CT and PET/MRI showed 94.2% lesion detection capability in multiple 
myeloma patients. Using the two devices, same uptake on PET images 
were detected, however, two different imaging time points had been 
applied. These data confirm that the lesion detection capability of PET/
MRI in myeloma is not inferior to PET/CT imaging. 
The low SUVmax values indicate that the metabolic activity in 
myeloma is mostly low. Only one patient had extremely high SUVmax 
value (17.9) who died soon after the treatment start. The SUVmax 
values did not correlate significantly with any clinical parameters.
The 18F-FDG PET metabolic tumor volume assessment provides 
information about the 3D structure and the intratumoral biological 
variations of tumors [15,16]. MTV has been found a predictor of the 
patient outcome in human solid tumors and proved to be superior to 
SUVmax [17,18]. The MTV measured by 18F-FDG PET may reflect the 
plasma cell mass throughout the whole body in PCM patients, thus it 
may provide a novel potential prognostic factor. 
The Salmon-Durie staging system was first developed to measure 
PCM tumour burden [19]. The assessment is difficult because a 
significant heterogeneity characterizes this disease at multiple levels 
such as clinical presentation, biologic characteristics, treatment 
response, and clinical outcome. Some years later, a more objective 
and feasible staging system, the ISS was introduced. It was established 
on the measurement of serum albumin and ß2-microglobulin levels. 
Figure 2b: Coronal T2 STIR MRI, PET and Fusioned PET/MRI images. T2 high intensity foci and focal radiopharmacon activity increase in right femur.The sceletal 
survey and other CRAB criterias were negative in a 76 years old woman with IgA-λ MM. (M-komp.: 11 g/l, bone marrow infiltration 40%)
Figure 3: Correlation between metabolic tumor volumen and β2 microglobulin level. In the case of 2 patients who demonstrated a negative pattern, and in the case 
of 4 patients, who have a diffuse pattern in bone marrow, MVT was not calculated by our method.
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However, cut-off levels remained a matter of controversy because in 
the advanced ISS the tumour burden and renal failure could increase 
the ß2-microglobulin levels [20,21]. Therefore, this system cannot 
provide a good estimate for tumour burden or risk stratification in 
patients with renal failure. 
We compared and correlated MTV with the most important clinical 
and hematologic parameters of PCM patients. The strong correlation 
between ß2-microglobulin and MTV, or between ISS stage and MTV 
could provide a potential new marker for tumour mass measurement 
at diagnosis and during the course of treatment. 9. Conclusion
The MRI combined with the 18F-FDG PET provides a good 
opportunity for both, functional and morphologic assessments of 
bone lesions in PCM patients. The combination also allows a more 
precise anatomic localization of the PCM lesions and may provide new 
perspectives in the early diagnosis and prognosis establishments. Our 
study has some limitations since a low number of patients were studied, 
so these results should be considered as the preliminary findings of an 
ongoing study. 
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